How many treatments can restore the skin's full function?

Fixed catalogue

A list of treatment options chosen before the comparison begins. Its contents and rules for distinguishing options are not supplied.

Q0

The pipeline's label for the full set of requirements an option must satisfy. Its expansion, detailed measurements, and pass conditions are not supplied.

Treatment option

In this question, the complete arrangement of treatment, continuing maintenance, and required care. A result for that arrangement does not automatically describe the treatment used alone.

Random assignment

Allocation of participants to comparison groups by chance. The requested ten-year comparison uses this method, but no supplied source establishes that such a comparison tested the fixed catalogue.

Skin function

How well skin performs the jobs being assessed. The question seeks restoration toward younger skin, but the supplied material does not specify all relevant functions or a reference level.

Collagen

A structural protein discussed here as a supplement, material in an implant, and substance formed within skin. These are different uses and do not constitute a single interchangeable treatment.

Hydrolyzed collagen

Collagen broken into smaller pieces. S1 concerns taking it as a supplement.

Skin elasticity

How readily skin returns toward its previous shape after being stretched or deformed. An improvement in this measurement alone does not establish restoration of every skin function.

Skin hydration

The water content of skin. It is one of the measurements reported in S1.

Microneedling

A skin treatment involving small needle punctures. S3 discusses its use across different skin conditions and types.

Radiofrequency microneedling

Microneedling combined with delivery of energy that heats tissue. S2 discusses subsequent skin restructuring and collagen formation.

Skin restructuring

Changes in the organization of skin tissue, also called remodeling. S2 describes it as a gradual process rather than an immediate completed change.

Placebo

A comparison treatment intended to resemble the tested treatment without its active component. S4's title identifies its study as placebo-controlled.

Fibroblasts

Cells that produce structural material in tissue, including collagen. S7 studies transplantation of a person's own fibroblasts.

Open-label study

A study in which treatment identity is not concealed from participants and investigators. S7 also has only one treatment group, limiting the comparisons its design provides.

Collagen-gel implant

A collagen-containing gel placed in tissue. S8 reports results for such an implant in mice, without establishing the requested long-term human outcome.

Light-related skin damage

Skin damage associated with light exposure, termed photoaging in S8. The mouse model represents this particular kind of damage rather than every aspect of human skin aging.

Skin density

A measure of how densely skin tissue is structured. The supplied quotation from S8 reports an improvement without specifying the measurement method or its magnitude.

Cell therapy

Treatment using cells. This is a broad class of interventions; S9's coverage of clinical applications does not establish that any particular option meets the question's combined requirements.

Delayed harms

Unwanted effects that appear after time has passed. Their absence during a short study does not establish their absence over ten years.

• No listed option qualifies If every option fails at least one requirement, the qualifying count would be zero. An option could still improve a skin measurement while failing the combined standard because its benefit does not last, its risk is unacceptable, or its required care is impractical.
• Some listed options qualify Only options that satisfy every requirement would enter the count. Qualification would apply to each complete treatment-and-care arrangement, so it would not establish the same result for the treatment without that care.
• Every listed option qualifies The qualifying count would equal the number of distinct options in the fixed catalogue. That result would cover the tested arrangements and requirements, without establishing qualification for treatments outside the catalogue.
• The count remains unresolved If long-term results or required measurements are missing, some options cannot be classified as passing or failing. Treating those unresolved options as failures would confuse missing evidence with demonstrated failure.

A short-term improvement in a skin measurement does not establish that restored function lasts for ten years. Continuing treatment and required care are part of what must remain practical throughout that period. Participants leaving the study and harms appearing later also affect whether an option meets the combined requirements. Counting an option from an early improvement alone could therefore overstate the number that deliver the full combination of lasting benefit, acceptable risk, and feasible use.